We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

Back to rankings

130 hedge funds and large institutions have $766M invested in Immunomedics Inc in 2017 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 51 increasing their positions, 40 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more funds holding in top 10

Funds holding in top 10: 3 → 7 (+4)

74% more capital invested

Capital invested by funds: $440M → $766M (+$326M)

56% more call options, than puts

Call options by funds: $41.9M | Put options by funds: $26.9M

29% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 21

28% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 40

5% more funds holding

Funds holding: 124 → 130 (+6)

Holders
130
Holders Change
+6
Holders Change %
+4.84%
% of All Funds
3.24%
Holding in Top 10
7
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+133.33%
% of All Funds
0.17%
New
27
Increased
51
Reduced
40
Closed
21
Calls
$41.9M
Puts
$26.9M
Net Calls
+$15M
Net Calls Change
+$5.2M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$27.9M
2
O
OrbiMed
New York
+$26M
3
PAI
Palo Alto Investors
California
+$21.1M
4
Millennium Management
Millennium Management
New York
+$17M
5
FCMI
Foresite Capital Management III
California
+$12.4M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$21.9M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.74M
3
6CM
683 Capital Management
New York
-$3.51M
4
SFM
Sphera Funds Management
Israel
-$2.81M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
DAFNA Capital Management
California
$5.63M +$2.7M +385,126 +152%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$5.55M +$1.15M +163,920 +35%
AC
28
Ascend Capital
California
$5.12M +$4.07M +579,943 New
SFM
29
Sphera Funds Management
Israel
$4.86M -$2.81M -400,000 -42%
CS
30
Candriam SCA
Luxembourg
$4.86M +$281K +40,000 +8%
RPAM
31
Rhenman & Partners Asset Management
Sweden
$4.68M +$351K +50,000 +10%
EI
32
EAM Investors
California
$4.48M +$2.6M +370,086 +270%
Two Sigma Investments
33
Two Sigma Investments
New York
$4.33M +$2.03M +288,787 +144%
Deutsche Bank
34
Deutsche Bank
Germany
$3.75M +$1.21M +172,122 +68%
Invesco
35
Invesco
Georgia
$3.19M +$2.54M +361,607 New
6CM
36
683 Capital Management
New York
$2.87M -$3.51M -500,000 -61%
IHM
37
Iguana Healthcare Management
New York
$2.87M -$176K -25,000 -7%
Wells Fargo
38
Wells Fargo
California
$2.63M +$69.3K +9,863 +3%
TCIM
39
TIAA CREF Investment Management
New York
$2.47M +$100K +14,261 +5%
Parallax Volatility Advisers
40
Parallax Volatility Advisers
California
$2.47M +$1.96M +279,709 New
PPA
41
Parametric Portfolio Associates
Washington
$2.47M +$789K +112,328 +67%
B
42
Bailard
California
$2.45M -$267K -38,000 -12%
GAM
43
Gotham Asset Management
New York
$2.39M +$1.9M +270,496 New
PVI
44
Pura Vida Investments
New York
$2.27M -$2.02M -288,200 -53%
CEP
45
Chicago Equity Partners
Illinois
$2.14M -$853K -121,495 -33%
Allianz Asset Management
46
Allianz Asset Management
Germany
$1.74M -$34.7K -4,947 -2%
AI
47
Axiom Investors
Connecticut
$1.74M +$310K +44,153 +29%
Morgan Stanley
48
Morgan Stanley
New York
$1.73M -$1.2M -171,515 -47%
Charles Schwab
49
Charles Schwab
California
$1.66M +$185K +26,400 +16%
TA
50
Teachers Advisors
New York
$1.64M -$29.2K -4,164 -2%
1
2
3 4 5

IMMU Hedge Fund Activity: Q2 2017 in Review

130 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q2 2017, worth a combined $766M — up 74% from $440M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new IMMU positions and 21 closed out — a net gain of 6 holders — while 51 added to existing stakes and 40 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $27.9M. The largest seller was Redmile Group, exiting entirely with an estimated $21.9M sold.

  • 130 institutional investors held Immunomedics Inc (IMMU) as of Q2 2017, up from 124 in Q1 2017.
  • Funds reported $766M of Immunomedics Inc stock for Q2 2017, up 74% quarter-over-quarter.
  • 27 funds opened new Immunomedics Inc positions in Q2 2017 and 21 closed out, a net change of +6 holders.
  • The largest Immunomedics Inc buyer in Q2 2017 was Fidelity Investments, an estimated $27.9M added.
  • The largest Immunomedics Inc seller in Q2 2017 was Redmile Group, an estimated $21.9M sold.

Based on aggregated 13F filings for Q2 2017.